Form 8-K · Current Report · Filed 2026-04-28
Gilead Sciences Completes Acquisition of Arcellx
Gilead Sciences, Inc. has completed its acquisition of Arcellx, Inc. for $115 per share in cash and one contingent value right (CVR) of $5 per share, totaling approximately $7.8 billion. The acquisition provides Gilead with full control of an investigational BCMA-directed CAR T-cell therapy for multiple myeloma, anitocabtagene autoleucel (anito-cel). The transaction is expected to reduce Gilead's GAAP and non-GAAP 2026 diluted EPS by approximately $5.57 - $5.67, with modest dilution in 2026 and 2027, and accretion thereafter, subject to FDA approval of anito-cel.
- Filer
- Gilead Sciences Inc. GILD · NASDAQ
- Filed
- Accession
- 0001104659-26-049874
- CIK
- 0000882095
- Signal
- High impactHealthcare
- Source
- Official filing on sec.gov ↗
Items reported
Reported Item
Market reaction
Close before filing
$127.75
Next session
+0.9%
Since filing
+1.9%
Latest close
$130.21
What happened, not what will happen — closing prices around the filing date.
Precedent
Previous filings from GILD reporting the same item, with the next session's move:
Insider tape
Within 45 days of this filing, GILD insiders reported 25 Form 4 transactions — net selling of $5.3M.
About Gilead Sciences Inc.
Gilead Sciences Inc. is a biopharmaceutical company that focuses on researching, developing, and commercializing innovative medicines in areas of unmet medical need. It is globally recognized for its distinguished work, particularly in the treatment of HIV, liver diseases such as hepatitis B and C, and various forms of cancer. The company's portfolio includes groundbreaking antiviral therapies and a robust pipeline of investigational drugs. Headquartered in Foster City, California, Gilead Sciences Inc. significantly contributes to the healthcare sector by extending the lives of patients with serious illnesses worldwide. Through strategic partnerships and continuous innovation, Gilead remains at the forefront of modern medicine, enhancing its role in the global pharmaceutical market.
Never miss another GILD filing
Profitelligence watches EDGAR around the clock and alerts you within seconds.